We failed to find a record ofintra-abdominal granuloma annulare lesions, and this case apyars to be the first of visceral granuloma annulare. The relation -tveen diabetes mellitus and generalised granuloma annulare has been a subject of speculation for years but remains unclear. Haim et al reported 13 patients with generalised granuloma annulare, three of whom had overt mild non-insulin dependent diabetes and seven others carbohydrate intolerance after provocative oral prednisolone.3 Other studies, however, have not confirmed this observation. A more recent report has suggested an association between granuloma annulare and insulin dependent diabetes.4 The relation between diabetes and granuloma annulare is made more complex by the histological appearance of necrobiosis lipoidica diabeticorum, granuloma annulare, and rheumatoid nodules. Each ofthese conditions includes collagen necrobiosis, and all three variants have been seen in a patient who had insulin dependent diabetes and a sister with rheumatoid arthritis.5 The histological similarities among these conditions are so great that they may share the same or a very similar pathogenesis. Immune complex deposition seems the most probable common pathway.
Discussion-
We failed to find a record ofintra-abdominal granuloma annulare lesions, and this case apyars to be the first of visceral granuloma annulare. The relation -tveen diabetes mellitus and generalised granuloma annulare has been a subject of speculation for years but remains unclear. Haim et al reported 13 patients with generalised granuloma annulare, three of whom had overt mild non-insulin dependent diabetes and seven others carbohydrate intolerance after provocative oral prednisolone. 3 Other studies, however, have not confirmed this observation. A more recent report has suggested an association between granuloma annulare and insulin dependent diabetes. 4 The relation between diabetes and granuloma annulare is made more complex by the histological appearance of necrobiosis lipoidica diabeticorum, granuloma annulare, and rheumatoid nodules. Each ofthese conditions includes collagen necrobiosis, and all three variants have been seen in a patient who had insulin dependent diabetes and a sister with rheumatoid arthritis. 5 The histological similarities among these conditions are so great that they may share the same or a very similar pathogenesis. Immune complex deposition seems the most probable common pathway.
Finally, in our patient there appeared to be a relation between diabetic control and the granuloma annulare. Poor diabetic control was associated with an exacerbation of the lesion, which in turn resulted in excessive working of the ileostomy, which was evident whatever the cause of his poor diabetic control. Biopsy sections of the skin and mesenteric nodes showed several discrete foci of connective tissue necrosis in the dermis and subcutaneous fat. The zones of necrosis were surrounded by histiocytes showing well marked palisading (figure). The histiocyte reaction was not strikingly tuberculoid. There were no giant cells, and no evidence of arteritis was detected. Haemophiliacs who have received treatment with lyophilised clotting factor concentrate are at increased risk of AIDS. Inverted ratios of T helper to T suppressor lymphocytes have been reported m haemophiliacs in the absence of infection with HIV,9 10 and it has been suggested that HIV is itself an opportunistic pathogen in an already immunocompromised host.9 1' We previously showed that lyophilised factor VIII concentrate in vitro has immunosuppressive properties in tissue cultures of human leucocytes. 12 The aim of this study was to determine whether haemophiliacs treated with factor concentrates show immunosuppression. The dinitrochlorobenzene skin test is considered to be the best single test to evaluate the cell mediated immune response in vivo3'14 and measures a person's ability to respond to a new antigen, as dinitrochlorobenzene is rarely encountered. The score on dinitrochlorobenzene testing was compared with exposure to clotting factor and HIV antibody state.
Patients and methods
We studied 29 patients with clinically severe haemophilia (factor VIII or IX concentration <50U/1) attending the Glasgow adult haemophilia centre, including 12 of 15 patients known to be seropositive for antibody to HIV. All patients were examined for features of disease related to HIV. Case records were examined for consumption of clotting factor concentrate over the previous four years, and the mean annual exposure to clotting factor was calculated. The presence of transaminasaemia and previous exposure to hepatitis B virus, as assessed by antigen and antibody testing (Abbott) at routine clinic visits was also noted.
Dinitrochlorobenzene testing A modified dinitrochlorobenzene test was performed in each case; the method has been described previously.' Briefly, patients were sensitised to dinitrochlorobenzene (2000 Ftg dissolved in 0-1 ml acetone) on the dominant forearm. After 14 days the patient was rechallenged with five doses of dinitrochlorobenzene (30, 15, 7 5, 3 7, and 1 8 Ftg) on the opposite forearm. The reaction was assessed after 48 hours as follows: 0 no reaction or erythema only; 1 erythema and induration confined to the patch; 2 erythema and induration extending beyond the patch; 3 as for 2, plus blistering. The maximum possible score was 15. Lymphocyte subsets-At the time of rechallenge with dinitrochlorobenzene blood was withdrawn for enumeration of the absolute numbers of T helper and T suppressor lymphocyte subsets. Mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation. T lymphocyte subpopulations were measured bv indirect immunofluorescence, using monoclonal antibodies to leu-3 and leu-2 as phenotypic markers for helper-inducer and suppressor-cytotoxic subsets, respectively, and counted using a cell sorter analyser activated by fluorescein (Becton-Dickinson).
Serological Dinitrochlorobenzene testing-In a previous study from our area using the same method of dinitrochlorobenzene testing the median score in normal subjects was 9 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . " All the patients in the present study had a score below 9 ( fig 1) . The median score in our patients was 3 (range 0-8): this was significantly different from normal (p<0001). In patients positive for HIV the median score was 1 (range 0-8): this was significantly different from normal (p<0001). Among the three patients with clinical features of disease related to HIV the score was 0 in the patient with thrombocytopenia and 0 and 4 in the two patients with lymphadenopathy. In seronegative patients the median score was 4 (range 0-8): this was significantly different from normal (p<0001) but not significantly different from the score in the seropositive patients.
Lymphocyte subsets-The Consumption of clotting factor-The median annual consumption of clotting factor over four years in all patients was 49608 units (range 5104-190 925). The median consumption in seropositive patients was 97 250 units (range 5104-190 925) and in seronegative patients 32 375 units (range 9925-92 500). This difference was not significantly different (p<0 05). An inverse correlation was noted between increasing usage of clotting factor and decreasing score on dinitrochlorobenzene all patients (fig 2) (r=-0 3,   p<005 ). In seronegative patients with a score less than normal (<4) the median consumption of clotting factor was 59685 units (range 21 175-92 500): this was significantly more than that in seronegative patients with a response in the normal range (median 22 899 units, range 9925-91 925; p<002). An inverse correlation was noted in all seronegative patients between consumption of clotting factor and score on dinitrochlorobenzene testing (r= -0 405, p<005), but the correlation in seropositive patients was not significant (r=0 08); there was no significant difference, however, between the correlations in the seropositive and seronegative groups.
Hepatic dysfunction-There was no significant association between results of dinitrochlorobenzene testing and the presence of transaminasaemia or exposure to hepatitis B virus.
Discussion
The response to dinitrochlorobenzene evaluates both the afferent and efferent arms of the immune response: it is therefore a measure of a patient's current cell mediated immune state. Our results show that all patients with severe haemophilia treated with factor VIII concentrate had a response below the median normal value, and in 19 of the 29 patients studied the response was on or below the lower limit of the normal range (that is, -4). In addition, the response was impaired in patients seronegative for antibody to HIV. This is the first report to show a depressed cell mediated immune response in vivo in haemophiliacs in the absence of antibody to HIV. In patients negative for antibody to HIV the response to dinitrochlorobenzene was inversely related to consumption of clotting factor. In particular, patients who had a subnormal response had used significantly more factor concentrate than patients with a response in the normal range. This association of consumption of clotting factor with reduced cell mediated immunity may be due to transmission ofviral infection, to a direct chemical effect of concentrate, or to an indirect effect mediated via the immune system. Concomitant serological studies excluded the possibility of an incidental viral infection. Infection with HIV in the absence of antibody was considered to be unlikely, and no patient in the seronegative group had features of disease related to HIV. In our patient population HIV seroconversion occurred during 1980-4,"7 and in a previous report we showed that seroconversion was associated with use ofimported American concentrate."8 No further seroconversions were recorded in these patients after 1984, when all patients began to receive locally prepared factor concentrate from an area with a low prevalence of disease related to HIV. In addition, isolates of virus from seronegative patients are exceptional."9 We therefore suggest that the depression in cell mediated immunity is probably due to either a direct effect or an immunological consequence of infusion of factor concentrate.
In a previous study of our patients Forwell et al reported high circulating levels of FcY receptor antibody.n This antilymphocyte antibody develops after repeated blood transfusions, and its presence correlates directly with survival of renal allografts.2" The FcY receptor is an important immunoregulatory protein,2 and blocking of this receptor with antibody or immune complexes stimulates a non-specific T suppressor cell response23 which could additionally inhibit macrophage activation or T helper function. Excessive activity of T suppressor cells may therefore account for the abnormalities seen in our seronegative patients on dinitrochlorobenzene testing.
In the 12 seropositive patients the score on dinitrochlorobenzene testing was significantly below normal (p<OOOl), and nine of the patients had a score below the normal range. The score did not differ significantly, however, from that in seronegative patients. We could not show a correlation in seropositive patients between the score and consumption of clotting factor. Both these negative findings, however, may have been due to the smaller numbers in this group.
In summary, therefore, our results suggest that cell mediated immunity is decreased in patients with severe haemophilia treated with factor VIII concentrate and that this is related to the amount of factor VIII used. Whether this abnormality is related to risk of infection with HIV or to its sequelae, or both, is not yet known. Though no significant difference in the score on dinitrochlorobenzene testing was observed between seronegative and seropositive patients, infection with HIV in the seropositive patients was fairly recent. Future studies of the response to dinitrochlorobenzene in patients who have had infection with HIV for a longer period may well show lower responses, as immunosuppression induced by HIV may take many years to become firmly established.
